Catalyst Pharmaceuticals (NASDAQ:CPRX) Lowered to “Hold” Rating by Robert W. Baird

Catalyst Pharmaceuticals (NASDAQ:CPRX) was downgraded by equities researchers at Robert W. Baird from a “strong-buy” rating to a “hold” rating in a research report issued on Thursday,Zacks.com reports.

Several other equities research analysts have also commented on the stock. Weiss Ratings reiterated a “buy (b-)” rating on shares of Catalyst Pharmaceuticals in a research note on Friday, March 27th. Wall Street Zen lowered Catalyst Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday. Oppenheimer lowered Catalyst Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research report on Thursday. Citigroup lowered Catalyst Pharmaceuticals from a “buy” rating to a “neutral” rating and decreased their target price for the company from $35.00 to $31.50 in a research report on Friday. Finally, Cantor Fitzgerald raised Catalyst Pharmaceuticals to a “strong-buy” rating in a research report on Friday, March 27th. Three research analysts have rated the stock with a Strong Buy rating, one has issued a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, Catalyst Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $32.17.

Catalyst Pharmaceuticals Stock Performance

NASDAQ:CPRX opened at $31.15 on Thursday. The firm has a market cap of $3.81 billion, a price-to-earnings ratio of 18.43, a price-to-earnings-growth ratio of 1.01 and a beta of 0.72. Catalyst Pharmaceuticals has a 52 week low of $19.05 and a 52 week high of $32.56. The firm has a 50-day moving average price of $25.31 and a two-hundred day moving average price of $23.93.

Institutional Investors Weigh In On Catalyst Pharmaceuticals

Several large investors have recently added to or reduced their stakes in the company. PNC Financial Services Group Inc. increased its holdings in Catalyst Pharmaceuticals by 4.7% in the 1st quarter. PNC Financial Services Group Inc. now owns 10,554 shares of the biopharmaceutical company’s stock worth $261,000 after acquiring an additional 474 shares during the last quarter. Convergence Investment Partners LLC increased its holdings in Catalyst Pharmaceuticals by 106.8% in the 1st quarter. Convergence Investment Partners LLC now owns 75,682 shares of the biopharmaceutical company’s stock worth $1,874,000 after acquiring an additional 39,092 shares during the last quarter. Meeder Asset Management Inc. purchased a new stake in Catalyst Pharmaceuticals in the 1st quarter worth about $257,000. Dimensional Fund Advisors LP increased its holdings in Catalyst Pharmaceuticals by 14.5% in the 1st quarter. Dimensional Fund Advisors LP now owns 3,429,615 shares of the biopharmaceutical company’s stock worth $84,908,000 after acquiring an additional 433,318 shares during the last quarter. Finally, AlphaCentric Advisors LLC increased its holdings in Catalyst Pharmaceuticals by 5.7% in the 1st quarter. AlphaCentric Advisors LLC now owns 23,286 shares of the biopharmaceutical company’s stock worth $577,000 after acquiring an additional 1,266 shares during the last quarter. Hedge funds and other institutional investors own 79.22% of the company’s stock.

Catalyst Pharmaceuticals News Summary

Here are the key news stories impacting Catalyst Pharmaceuticals this week:

• Positive Sentiment: Angelini Pharma agreed to acquire Catalyst Pharmaceuticals for about $4.1 billion, or $31.50 per share in cash, which is above where the stock had been trading and typically supports a takeover premium. Closing is expected in the third quarter of 2026. Italy’s Angelini Pharma to buy Catalyst Pharmaceuticals for $4.1 billion
• Positive Sentiment: Catalyst also announced a settlement of its FIRDAPSE patent litigation with Hetero Labs, pushing any potential generic competition to January 2035 and resolving all pending FIRDAPSE patent disputes. That reduces legal overhang for the business. Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE Patent Litigation with Hetero Labs Ltd.
• Neutral Sentiment: The company canceled its first-quarter 2026 conference call and webcast, which may have drawn attention but does not appear to be a major fundamental development on its own. Catalyst Pharmaceuticals Cancels First Quarter 2026 Conference Call and Webcast
• Negative Sentiment: Stephens downgraded Catalyst to Equal Weight from Overweight, which can weigh on sentiment even though the downgrade may be overshadowed by the acquisition bid. Stephens & Co. downgrades Catalyst Pharmaceuticals (CPRX)
• Negative Sentiment: Law firms announced shareholder investigations into whether Catalyst is receiving a fair price in the Angelini transaction, creating a small litigation-related overhang. Shareholder Alert: Ademi LLP investigates whether Catalyst Pharmaceuticals Inc. is obtaining a Fair Price for Public Shareholders

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).